A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1587, Issue 2-3, 2002, Pages 215-223

  Jackman, Ann L ^a   Melin, Camille J ^a   Kimbell, Rosemary ^a   Brunton, Lisa ^a   Aherne, G Wynne ^a   Theti, Davinder S ^a   Walton, Mike ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Folylpolyglutamyl synthetase; Ovarian cancer; Raltitrexed; Thymidylate synthase; ZD9331

Indexed keywords

CISPLATIN; FOLYLPOLYGLUTAMATE SYNTHASE; MESSENGER RNA; PLATINUM; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

CELL ASSAY; CELL LINE; COLON TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; OVARY TUMOR; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR CELL;

ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FOLIC ACID ANTAGONISTS; GENE EXPRESSION; HUMANS; OVARIAN NEOPLASMS; PEPTIDE SYNTHASES; QUINAZOLINES; RNA, MESSENGER; RNA, NEOPLASM; THIOPHENES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0037130283     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(02)00084-4     Document Type: Review

References (29)

1. Molecular regulation of expression of thymidylate synthase
2. ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer
3. Management of colorectal cancer: Defining the role of raltitrexed
4. The cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, non-polyglutamatable quinazoline-based inhibitor of thymidylate synthase
5. ZD9331: Preclinical and clinical studies
6. Phase I trial of ZD9331 in aduly patients with refractory solid malignancies adminsitered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks
7. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor, ZD1694 (Tomudex) in one mouse and three human cell lines
8. High thymidylate synthase may predict non-response in tumour and increased risk of toxicity in normal gastrointestinal mucosa following treatment with raltitrexed
9. Tomudex: Clinical Development
10. Biological properties of ten human ovarian carcinoma cell lines: Calibration in vitro against four platinum complexes
11. Characterisation of a cis-dianninedichloroplatinum (II)-resistant human ovarian carcinoma cell line and its use in evaluation of platinum analogs
12. A novel class of lipophilic quinazoline-based folic acid analgues: Cytotoxic agents with a folate-independent locus
13. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity
14. 10-propargyl-5,8-dideazafolic acid (CB 3717): Development, characterisation and cross-resistance studies
15. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
16. Expression cloning of a human cDNA encoding folylpoly(γ-glutamate) synthetase and determination of its primary structure
17. Molecular cloning of DNA sequences complimentary to mouse thymidylate synthase messenger RNA
18. Effects of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line
19. Thymidine kinase, thymidylate synthase, and dohydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's anticancer drug screen
20. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibtors, in 13 nonselected colon cancer cell lines
21. The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ™ in human leukaemia and colorectal carcinoma cell lines
22. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
23. Modulation of antimetabolite effects: Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB 3717
24. Folylpoly-γ-glutamate synthetase gene mRNA slice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues
25. Misincorporation of uracil into DNA may result in cell cycle progression and greater sensitivity to thymidylate synthase inhibitors
26. BCL-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways
27. Folylpolyglutamyl synthetase mRNA expression in ovarian cancer
28. Pharmacodynamic and growth inhibition consequences of α-folate receptor (α-FR) mediated transport of ZD9331 in human tumor cell lines that co-express the α-FR and the reduced-folate carrier
29. Trophoblast and ovarian cancer antigen LK26: Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein